Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dutch national guidelines for locally recurrent rectal cancer.
Piqeur F, Creemers DMJ, Banken E, Coolen L, Tanis PJ, Maas M, Roef M, Marijnen CAM, van Hellemond IEG, Nederend J, Rutten HJT, Peulen HMU, Burger JWA. Piqeur F, et al. Among authors: roef m. Cancer Treat Rev. 2024 Jun;127:102736. doi: 10.1016/j.ctrv.2024.102736. Epub 2024 Apr 19. Cancer Treat Rev. 2024. PMID: 38696903 Review.
Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer.
Voogt ELK, van Zoggel DMGI, Kusters M, Nieuwenhuijzen GAP, Bloemen JG, Peulen HMU, Creemers GJM, van Lijnschoten G, Nederend J, Roef MJ, Burger JWA, Rutten HJT. Voogt ELK, et al. Among authors: roef mj. Ann Surg Oncol. 2020 Sep;27(9):3503-3513. doi: 10.1245/s10434-020-08362-4. Epub 2020 Mar 19. Ann Surg Oncol. 2020. PMID: 32193717
Metabolic positron emission tomography/CT response after induction chemotherapy and chemo(re)irradiation is associated with higher negative resection margin rate in patients with locally recurrent rectal cancer.
van Zoggel DMGI, Voogt ELK, van Lijnschoten IG, Cnossen JS, Creemers GJ, Nederend J, Bloemen JG, Nieuwenhuijzen GAP, Burger PJWA, Lardenoije SGGF, Rutten HJT, Roef MJ. van Zoggel DMGI, et al. Among authors: roef mj. Colorectal Dis. 2022 Jan;24(1):59-67. doi: 10.1111/codi.15934. Epub 2021 Nov 16. Colorectal Dis. 2022. PMID: 34601782
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K, Schaap DP, Voogt ELK, Buffart TE, Verheul HMW, de Groot JWB, Verhoef C, Melenhorst J, Roodhart JML, de Wilt JHW, van Westreenen HL, Aalbers AGJ, van 't Veer M, Marijnen CAM, Vincent J, Simkens LHJ, Peters NAJB, Berbée M, Werter IM, Snaebjornsson P, Peulen HMU, van Lijnschoten IG, Roef MJ, Nieuwenhuijzen GAP, Bloemen JG, Willems JMWE, Creemers GJM, Nederend J, Rutten HJT, Burger JWA. van den Berg K, et al. Among authors: roef mj. BMC Cancer. 2022 Sep 6;22(1):957. doi: 10.1186/s12885-022-09947-w. BMC Cancer. 2022. PMID: 36068495 Free PMC article.
Locally recurrent rectal cancer: Oncological outcomes for patients with a pathological complete response after neoadjuvant therapy.
Nordkamp S, Piqeur F, van den Berg K, Tolenaar JL, van Hellemond IEG, Creemers GJ, Roef M, van Lijnschoten G, Cnossen JS, Nieuwenhuijzen GAP, Bloemen JG, Coolen L, Nederend J, Peulen HMU, Rutten HJT, Burger JWA. Nordkamp S, et al. Among authors: roef m. Br J Surg. 2023 Jul 17;110(8):950-957. doi: 10.1093/bjs/znad094. Br J Surg. 2023. PMID: 37243705
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy.
Valkema MJ, Beukinga RJ, Chatterjee A, Woodruff HC, van Klaveren D, Noordzij W, Valkema R, Bennink RJ, Roef MJ, Schreurs W, Doukas M, Lagarde SM, Wijnhoven BPL, Lambin P, Plukker JTM, van Lanschot JJB. Valkema MJ, et al. Among authors: roef mj. Nucl Med Commun. 2023 Aug 1;44(8):709-718. doi: 10.1097/MNM.0000000000001707. Epub 2023 May 3. Nucl Med Commun. 2023. PMID: 37132272 Free PMC article.
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group. Noordman BJ, et al. Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29861116
32 results